Who bought the other 47 shares today? Haha.

No volume here on the “rumors”. Just the sound of silence.

I bought another 100k shares when I read the rumor. But then I read the disclaimer.

Doh.

https://t.co/QkHdhnIcYi?ssr=true

I keep wondering how the expected mOS might change in final data for patients that live 36 months. Interim data indicated 88 months. All patients in this trial are now >36 months. That data should be mature now. Better yet, it will be great to find out how many of those >36 month survivors were DCVAX and how many were placebo.

See ya jd. Thanks for all your “insight”

At sea or at the beach.

Have fun at sea Marz.

Great chart. It seems as if momentum starts to build, the selling volume picks up. I’m pretty sure retailers aren’t selling at these prices, so the question really is...who is selling?

Senti - maybe you could post some German, Yiddish, or Arabic logic to spur some buying here.

Math is a universal language, yet our markets seem illiterate.

No reason to talk until they have positive data in hand. What are they gonna say? We promise that DCVax is going to work?

I believe LP said they had a home run. Then LP threw 4.5 million of her own money at this. Interim results were then very promising. If all that didn’t instill confidence, then I’m pretty sure no other English words exist to make people want to invest here and boost the price. Maybe there is a statement they could make in another language that could do the trick.

Nothing more to do here but be patient and wait for topline data.

It all depends on their P3 data.

I’ve bought added for just over a year now. I wonder who is selling?

My sell orders start small at around $4.50. They get bigger between $20 and $100.

Manipulators can cover there.

If it truly is manipulation, the short squeeze will be epic with good news. I truly hope this is being manipulated. That will mean a well stoked fire if we hit on topline

Maybe “crushed it” was too vague of a statement. I should have stated...the interim blended data demonstrated a meaningful improvement in survival outcome over the historical standard of care. It also indicated an unknown cause for this survival improvement for which there was no other known prognostic factor. One can deduce that the cause for this improvements is quite likely the drug being studied in this trial.

I’m sorry the paper crushed your spirits. Perhaps you were searching for something more here.

We’ll get topline PR before the end of the year. I expect a Merry Christmas for all NWBO shareholders. Interim data crushed it. No more dilution since June. They’re prepping for something big and management is heavily invested in this data. This study could indicate a major change in cancer therapy moving forward.

Oops. Missed that

We already know that they are in financial dire straights. I don’t need a quarterly report to reinforce that point. The promise here isn’t the financial strength of the company. It’s the potentially disruptive technology that they own.

Good point. I should just point out that scientists and doctors are human too. We all have the capability for unethical behavior. There may be no corruption, but it does feel like there is quite the uphill battle proving the science on something that has as much potential to disrupt many business models. DCVAX has that potential.

The world of science is just as corrupt as any other industry. Just because one has an MD or PhD, it doesn’t mean they ever aced ethics. Self promotion and competition abound everywhere. It’s human nature.

In the face of all of this, if NWBO management gets extremely positive P3 results and product approval, we should applaud their massive effort to navigate and overcome extremely hostile forces.

All this political and and scientific conflict of interest is contrasted by Dr. Liau, who has no financial tie to NWBO. She’s in this for the pure science of what she is trying to give to patients and our world. Imagine a cure for cancer for 1/3 of all patients with no side effects. Imagine the benefits that would have on our overtaxed health care system. Imagine the cost savings to Medicare and Medicaid. The only disease that may compare, in terms of cost to society, is diabetes.

I’m sure there are HUGE business model changes that would be effected by such a cure. I’m hoping that we get to witness such dynamics in our lifetime.

My shares aren’t for sale. Not at these prices.

Marz...

If NWBO hits $5, you should start handicapping biotechs for a living.

NWBO could dwarf them all with Direct approval.

For sure. Commercialization should come within 12 months. Demand will be huge right away due to the nature of this disease.

At $1.00 a share, NWBO will have plenty of cash to get things done. They’re called warrants and there’s roughly $50 million in warrant liability sitting out there.

NWBO could change the landscape of cancer care.

With how the results of this study could change a very entrenched and profitable business model, they need the study results to be statistically sound and the evidence irrefutable.

Thanks for this post and trial insights here. The biggest point is that the failure of one vaccine shouldn’t predict failure of a different one.

Think about it too. NWBO would not want to disclose this as a reason for the hold, as it could be a release of proprietary information. Why would they disclose that they were still optimizing their drug and manufacturing process to the competition?

If topline is 4-8 months increase in mOS, any idea what type of price increase would we be looking at?

Their transparency is pretty bad. That being said, the silence is probably warranted. They telegraphed the paper on interim data for a year and even after publishing it, their credibility was thrown into question. Linda Powers has said we have a home run here and then she put 4 million plus into the company. Actions speak louder than words. AF hasn’t invested a dime.

NWBO like?

It’s about time AF comes around.

Any thoughts on VTVT action today and competitive effect on NWBO? They published positive results on their head and neck immune cancer study.

I’m jealous. I want more at these prices.

Keep printing those shares Wall St! It’ll make the squeeze much more fun.

Most financial people are clueless to how science works.

I think the one thing we can assume here fairly obviously is that they are done diluting prior to results. If they were going to continue diluting, the idea was to keep going with small amounts of preferreds to raise funds. The conversion makes it obvious that dilution is over until results. I’d imagine they’re counting on positive results to generate a price increase and warrant money. With that money, they can fund their way to approval and the start of Direct trials. Once this company starts generating revenue, desperation will set in from BP. NWBO could soon be joining their ranks.

I agree. I think NWBO has a 20 billion market cap ahead within 5 years of approval. DCVax could change oncology market. It could change medicine. Side effects of cancer treatment? None. Imagine the cost savings.

As an addendum, one could assume that DCVax could trigger an abscopal effect. This is routinely seen in radiation and chemo patients.